Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 consolidation in inoperable stage III NSCLC
NCT05177497Phase 2Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Jan 2022
- Primary completion
- Jul 2024
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of retlirafusp alfa in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Primary endpoints: Adverse Events up to 2 years and Progression-Free Survival up to 2 years. Status: unknown.
02
Drugs
retlirafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05177497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177497.